Biomnis >> Resources & Documents >> Focus

Focus

Sidebar Image
Monitoring Anti-TNF-α Therapies in Chronic Inflammatory Disorders: Infliximab and Adalimumab

Date: November 2016

Anti-tumour necrosis factor (anti-TNF) therapy has, since the 1990s, become an important part of the management of several chronic inflammatory diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ankylosing spondylitis and severe psoriasis. The first anti-TNF drug to be approved for clinical use was infliximab; since then several more have been developed including adalimumab, golimumab, and etanercept.

Click here to access the full article »

Multi-Drug Resistant Organism Screening
Published March 2016

Biomnis Focus 5FU
Published: January 2016

Aspergillus Galactomannan
Published: April 2015

Constitutional Cyto- & Molecular Genetics: Karyotyping, FISH & CGH Array
Published: February 2015
ALPHA-1 ANTI-TRYPSIN DEFICIENCY
Published: January 2015
16S RNA PCR 2011
Published: January 2011
ACC 2011
Published: February 2011
ANCA 2011
Published: March 2011
Haemophilia A 2011
Published: April 2011
Malaria 2011
Published: May 2011
Multiple Myeloma 2011
Published: June 2011
Syphilis 2011
Published: July 2011
Factor VIII 2011
Published: August 2011